AGRN Gene Mutation Leads to Congenital Myasthenia Syndromes: A Pediatric Case Report and Literature Review

Abstract

The congenital myasthenia syndromes (CMS) are a group of autosomal recessive or autosomal dominant diseases that affect neuromuscular junctions. CMS caused by AGRN mutations is very uncommon typically characterized by ptosis, mild weakness, and proximal limb weakness. We report the case of an 8-year-old female who exhibited the onset of motor development retardation from infancy and slow progression to proximal muscle weakness. Repeated nerve stimulation at 3 Hz showed a clear decrement with 17%. Whole exon sequencing showed an AGRN gene compound heterozygous mutation (c.5009C >T and c.5078T > C). She was treated with salbutamol but without improvement. Then pseudoephedrine was adapted as a treatment choice and obtained remarkable curative effect. We have summarized and analyzed 12 patients who have been reported in the literature. An early age of onset and muscle weakness in the lower limbs are the main feature of an early AGRN gene mutation. Both types of AGRN-related CMS respond favorably to ephedrine. This is the first report showing that pseudoephedrine is effective as a choice for the treatment of AGRN-related CMS.

Keywords

congenital myasthenia syndromes - motor development retardation - whole exon sequencing - pseudoephedrine

Publikationsverlauf

Eingereicht: 14. Oktober 2019

Angenommen: 23. Januar 2020

Artikel online veröffentlicht:
28. März 2020

• References

• 1 Finsterer J. Congenital myasthenic syndromes. Orphanet J Rare Dis 2019; 14 (01) 57
• 2 Arican P, Gencpinar P, Cavusoglu D, Olgac Dundar N. Clinical and genetic features of congenital myasthenic syndromes due to CHAT mutations: case report and literature review. Neuropediatrics 2018; 49 (04) 283-288
• 3 Angelini C, Lispi L, Salvoro C, Mostacciuolo ML, Vazza G. Clinical and genetic characterization of an Italian family with slow-channel syndrome. Neurol Sci 2019; 40 (03) 503-507
• 4 Huzé C, Bauché S, Richard P. , et al. Identification of an agrin mutation that causes congenital myasthenia and affects synapse function. Am J Hum Genet 2009; 85 (02) 155-167
• 5 Engel AG. Congenital myasthenic syndromes in 2018. Curr Neurol Neurosci Rep 2018; 18 (08) 46
• 6 Souza PV, Batistella GN, Lino VC, Pinto WB, Annes M, Oliveira AS. Clinical and genetic basis of congenital myasthenic syndromes. Arq Neuropsiquiatr 2016; 74 (09) 750-760
• 7 Zhang Y, Dai Y, Han JN. , et al. A novel AGRN mutation leads to congenital myasthenic syndrome only affecting limb-girdle muscle. Chin Med J (Engl) 2017; 130 (19) 2279-2282
• 8 Maggi L, Bernasconi P, D'Amico A. , et al. Italian recommendations for diagnosis and management of congenital myasthenic syndromes. Neurol Sci 2019; 40 (03) 457-468
• 9 Kinali M, Beeson D, Pitt MC. , et al. Congenital myasthenic syndromes in childhood: diagnostic and management challenges. J Neuroimmunol 2008; 201-202: 6-12
• 10 Maselli RA, Fernandez JM, Arredondo J. , et al. LG2 agrin mutation causing severe congenital myasthenic syndrome mimics functional characteristics of non-neural (z-) agrin. Hum Genet 2012; 131 (07) 1123-1135
• 11 Nicole S, Chaouch A, Torbergsen T. , et al. Agrin mutations lead to a congenital myasthenic syndrome with distal muscle weakness and atrophy. Brain 2014; 137 (Pt 9): 2429-2443
• 12 Karakaya M, Ceyhan-Birsoy O, Beggs AH, Topaloglu H. A novel missense variant in the AGRN gene; congenital myasthenic syndrome presenting with head drop. J Clin Neuromuscul Dis 2017; 18 (03) 147-151
• 13 Feingold B, Mahle WT, Auerbach S. , et al; American Heart Association Pediatric Heart Failure Committee of the Council on Cardiovascular Disease in the Young; Council on Clinical Cardiology; Council on Cardiovascular Radiology and Intervention; Council on Functional Genomics and Translational Biology; and Stroke Council. Management of cardiac involvement associated with neuromuscular diseases: a Scientific Statement From the American Heart Association. Circulation 2017; 136 (13) e200-e231
• 14 Bogdanik LP, Burgess RW. A valid mouse model of AGRIN-associated congenital myasthenic syndrome. Hum Mol Genet 2011; 20 (23) 4617-4633
• 15 Vrinten C, van der Zwaag AM, Weinreich SS, Scholten RJ, Verschuuren JJ. Ephedrine for myasthenia gravis, neonatal myasthenia and the congenital myasthenic syndromes. Cochrane Database Syst Rev 2014; (12) CD010028